Johnson & Johnson-owned Janssen Pharmaceuticals has announce that it has entered into a research study in collaboration with Apple to discover whether wearable tech can help accelerate the diagnosis of atrial fibrillation (AFib) and improve the health outcome of those living with the condition.
The study will analyse the impact of Apple Watch on the early detection and diagnosis of AFib and the potential to improve outcomes, including the prevention of stroke.
“We’re excited about the potential of common, wearable technology to aid in the earlier detection and prevention of a frequent cause of stroke,” said Paul Stoffels, MD, Vice Chair of the Executive Committee and Chief Scientific Officer, Johnson & Johnson. “Too many people living with AFib are unaware of their risk, and earlier detection, diagnosis and treatment of AFib could significantly improve outcomes. Based on the insights generated through this research program, we may be able to develop new ways to detect other health conditions earlier in the future that also exhibit measurable physiological symptoms.”
“Through Apple Watch people have been able to learn more about their heart health, including discovering they have AFib. This kind of information empowers customers to follow up with the right treatment or even better, implement healthy habits aimed at prevention,” said Jeff Williams, Chief Operating Officer, Apple Inc. “We’re excited to work with Johnson & Johnson, a leader in the medical community, as we learn about the impact Apple Watch can have in delivering better health outcomes.”